Quantitative spatial profiling of immune populations in pancreatic ductal adenocarcinoma reveals tumor microenvironment heterogeneity and prognostic biomarkers

H Mi, S Sivagnanam, CB Betts, SM Liudahl, EM Jaffee… - Cancer research, 2022 - AACR
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with poor 5-year
survival rates, necessitating identification of novel therapeutic targets. Elucidating the …
被引用次数：49 相关文章
[PDF] archive.org

[PDF][PDF] Page Quantitative Spatial Profiling of Immune Populations in Pancreatic Ductal 2 Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and 3 …

H Mi, S Sivagnanam, CB Betts - scholar.archive.org
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with poor 5-45
year survival rates, necessitating identification of novel therapeutic targets. Elucidating the …
[PDF] aacrjournals.org

[PDF][PDF] Quantitative Spatial Profiling of Immune Populations in Pancreatic Ductal Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and Prognostic …

H Mi, S Sivagnanam, CB Betts, SM Liudahl, EM Jaffee… - Cancer Research, 2022 - AACR
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with poor 5-year
survival rates, necessitating identification of novel therapeutic targets. Elucidating the …
[HTML] nih.gov

[HTML][HTML] Quantitative Spatial Profiling of Immune Populations in Pancreatic Ductal Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and Prognostic …

H Mi, S Sivagnanam, CB Betts, SM Liudahl… - Cancer …, 2022 - ncbi.nlm.nih.gov
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with poor 5-year
survival rates, necessitating identification of novel therapeutic targets. Elucidating the …

Quantitative Spatial Profiling of Immune Populations in Pancreatic Ductal Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and Prognostic …

H Mi, S Sivagnanam, CB Betts… - Cancer …, 2022 - pubmed.ncbi.nlm.nih.gov
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with poor 5-year
survival rates, necessitating identification of novel therapeutic targets. Elucidating the …

Quantitative Spatial Profiling of Immune Populations in Pancreatic Ductal Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and Prognostic …

H Mi, S Sivagnanam, CB Betts, SM Liudahl… - Cancer …, 2022 - europepmc.org
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with poor 5-year
survival rates, necessitating identification of novel therapeutic targets. Elucidating the …

Quantitative Spatial Profiling of Immune Populations in Pancreatic Ductal Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and Prognostic …

H Mi, S Sivagnanam, CB Betts, SM Liudahl… - Cancer …, 2022 - ohsu.elsevierpure.com
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with poor 5-year
survival rates, necessitating identification of novel therapeutic targets. Elucidating the …

Quantitative Spatial Profiling of Immune Populations in Pancreatic Ductal Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and Prognostic …

H Mi, S Sivagnanam, CB Betts, SM Liudahl… - Cancer …, 2022 - pure.johnshopkins.edu
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with poor 5-year
survival rates, necessitating identification of novel therapeutic targets. Elucidating the …
[HTML] nih.gov

[HTML][HTML] Quantitative Spatial Profiling of Immune Populations in Pancreatic Ductal Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and Prognostic …

H Mi, S Sivagnanam, CB Betts, SM Liudahl… - Cancer …, 2022 - ncbi.nlm.nih.gov
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with poor 5-year
survival rates, necessitating identification of novel therapeutic targets. Elucidating the …